Volume 7, Issue 4 (11-2020)
JROS 2020, 7(4): 165-168 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Davoodabadi H, Malek F, Habibpanah B, Ghoojani A. The Efficacy of Platelet-Rich Plasma in the Treatment of Hemophilic Arthropathy. JROS 2020; 7 (4) :165-168
URL: http://jros.iums.ac.ir/article-1-2090-en.html
URL: http://jros.iums.ac.ir/article-1-2090-en.html
1- Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Childern’s Health, Shahid Beheshti University of Medical Sciences, Tehran.
Abstract: (1121 Views)
Background: The most clinical manifestation of hemophilia, as a congenital bleeding disorder, is the Intra-articular hemorrhage. The treatment of acute hemarthrosis with a sufficient amount of factor replacement will return the joint to the normal status.
Objectives: This study aimed to evaluate the efficacy of platelet-rich plasma in the treatment of hemophilic arthropathy patients to reduce and improve their pain and physical function.
Methods: Consecutive patients with hemophilic arthropathy were included in a self-control open-label trial in Mofid Children’s Hospital, Tehran, Iran. All participants received three platelet-rich plasma injections given two weeks apart. Also, the seriate self-reported and objective clinical outcomes were evaluated before and three months after the treatment.
Results: A total of 11 patients with hemophilic arthropathy involving 14 joints received three injections of platelet-rich plasma at 2-week intervals, at our center. All patients were evaluated with a visual analog scale, the hemophilia joint health score, and the range of motion, and bleeding events, before and after the treatment. Finally, 9 boys (81.8%) and 2 girls (18.2%) completed the study. The mean age of the participants was 14.7 years (range, 9-19 years). In all patients, statistically significant improvements were noted on all evaluated measures.
Conclusion: Platelet-rich plasma therapy is a reasonable and minimally invasive procedure that includes beneficial chondro-regenerative properties.
Objectives: This study aimed to evaluate the efficacy of platelet-rich plasma in the treatment of hemophilic arthropathy patients to reduce and improve their pain and physical function.
Methods: Consecutive patients with hemophilic arthropathy were included in a self-control open-label trial in Mofid Children’s Hospital, Tehran, Iran. All participants received three platelet-rich plasma injections given two weeks apart. Also, the seriate self-reported and objective clinical outcomes were evaluated before and three months after the treatment.
Results: A total of 11 patients with hemophilic arthropathy involving 14 joints received three injections of platelet-rich plasma at 2-week intervals, at our center. All patients were evaluated with a visual analog scale, the hemophilia joint health score, and the range of motion, and bleeding events, before and after the treatment. Finally, 9 boys (81.8%) and 2 girls (18.2%) completed the study. The mean age of the participants was 14.7 years (range, 9-19 years). In all patients, statistically significant improvements were noted on all evaluated measures.
Conclusion: Platelet-rich plasma therapy is a reasonable and minimally invasive procedure that includes beneficial chondro-regenerative properties.
Type of Study: Research Article |
Subject:
Knee surgery
Received: 2020/01/23 | Accepted: 2020/08/23 | Published: 2020/11/1
Received: 2020/01/23 | Accepted: 2020/08/23 | Published: 2020/11/1
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright © The Author(s);
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
